A Hospital Based Survey on Lung Cancer Related-pain in Northern China
NCT ID: NCT03189277
Last Updated: 2017-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2017-06-30
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology and Psychosocial Evaluation of Inpatient With Lung Opacity
NCT03498768
Detection of Lung Cancer by Plasma Lipids
NCT04287712
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
NCT05273827
A Preliminary Study on the Detection of Plasma Markers in Early Diagnosis for Lung Cancer
NCT04558255
Survival Outcomes of Lung Cancer
NCT03647098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a cross-sectional survey in 20 hospitals in Northern China. We designed two separate series of questions to be answered by patients and cancer management professionals. In the patient questionaire, we collect information on the prevalence, location, intensity, impact on life of lung cancer related pain. Questions on how doctors evaluate and manage the pain are included in both the patients' and physicians' surveys. In the doctors' questionaire, we also assess current situation of cancer pain educational programs attended in medical schools and post graduation through related questions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients (outpatient and inpatient) diagnosed with lung cancer visiting the participating hospitals on the designated day of investigation
* Informed consent must be obtained from the participating patients
2. The physician questionaire
* All physicians who receive lung cancer patients (outpatient and inpatient) in the participating hospitals on the designated day of investigation
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Cancer Hospital & Institute
OTHER
Chinese PLA General Hospital
OTHER
Beijing Chest Hospital
OTHER
307 Hospital of PLA
OTHER
Peking Union Medical College Hospital
OTHER
Beijing Chao Yang Hospital
OTHER
Peking University Third Hospital
OTHER
Peking University First Hospital
OTHER
The Hospital of Shunyi District Beijing
UNKNOWN
Daxing Hospital Beijing
UNKNOWN
Peking University Third Hospital Yanqing Hospital
UNKNOWN
Tianjin Medical University Cancer Institute and Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
Hebei Medical University Fourth Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
Shanxi Province Cancer Hospital
OTHER
Inner Mongolia People's Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
309th Hospital of Chinese People's Liberation Army
OTHER
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shi Yuankai
Vice president of National Cancer Center Chinese Academy of Medical Sciences
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CH-PT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.